Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Smit

Showing results (611-620 of 692) with videos related to

Pageof 70
Sort By:
International Journal of Cancer|February 13, 2004
Elevated hTERT mRNA levels: A potential determinant of bronchial squamous cell carcinoma (in situ)Peter J F Snijders, Roderick H J Breuer, Thomas G Sutedja, et al.
Future Oncology (London, England)|March 30, 2026
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Nature|October 25, 2019
Pan-cancer whole-genome analyses of metastatic solid tumoursPeter Priestley, Jonathan Baber, Martijn P Lolkema, et al.
Journal of Molecular Biology|October 20, 1999
Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppelR C Moore, I Y Lee, G L Silverman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 23, 2019
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA TrialRudolf M Huber, Karin H Hansen, Luis Paz-Ares Rodríguez, et al.
Targeted Oncology|June 18, 2024
Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab GovitecanDirk J A R Moes, Jeroen J M A Hendrikx, Henk-Jan Guchelaar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2022
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLCKarlijn Hummelink, Vincent van der Noort, Mirte Muller, et al.
Lung Cancer (Amsterdam, Netherlands)|November 18, 2024
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohortJ W T van der Wel, M Jebbink, D van den Broek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trialAndrea Ardizzoni, Marcello Tiseo, Luca Boni, et al.
Psychological Medicine|April 18, 2015
Predictors of treatment dropout in self-guided web-based interventions for depression: an 'individual patient data' meta-analysisE Karyotaki, A Kleiboer, F Smit, et al.
Pageof 70

Showing results (611-620 of 692) with videos related to

Sort By:
Pageof 70
International Journal of Cancer|February 13, 2004
Elevated hTERT mRNA levels: A potential determinant of bronchial squamous cell carcinoma (in situ)Peter J F Snijders, Roderick H J Breuer, Thomas G Sutedja, et al.
Future Oncology (London, England)|March 30, 2026
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Nature|October 25, 2019
Pan-cancer whole-genome analyses of metastatic solid tumoursPeter Priestley, Jonathan Baber, Martijn P Lolkema, et al.
Journal of Molecular Biology|October 20, 1999
Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppelR C Moore, I Y Lee, G L Silverman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 23, 2019
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA TrialRudolf M Huber, Karin H Hansen, Luis Paz-Ares Rodríguez, et al.
Targeted Oncology|June 18, 2024
Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab GovitecanDirk J A R Moes, Jeroen J M A Hendrikx, Henk-Jan Guchelaar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2022
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLCKarlijn Hummelink, Vincent van der Noort, Mirte Muller, et al.
Lung Cancer (Amsterdam, Netherlands)|November 18, 2024
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohortJ W T van der Wel, M Jebbink, D van den Broek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trialAndrea Ardizzoni, Marcello Tiseo, Luca Boni, et al.
Psychological Medicine|April 18, 2015
Predictors of treatment dropout in self-guided web-based interventions for depression: an 'individual patient data' meta-analysisE Karyotaki, A Kleiboer, F Smit, et al.
Pageof 70